Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05446857 · ClinicalTrials.gov registry record · Phase 2
Glecaprevir/Pibrentasvir for the Treatment of PTSD
A Phase 2 study, sponsored by White River Junction Veterans Affairs Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT05446857: Completed Phase 2 study, sponsored by White River Junction Veterans Affairs Medical Center.
NCT05446857 is a Phase 2 study that has completed, run by White River Junction Veterans Affairs Medical Center. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05446857, a Phase 2 study, has completed, sponsored by White River Junction Veterans Affairs Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
An open-label pilot study to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection (HCV).
Primary Outcome
Queries the frequency and intensity of symptoms of Post-traumatic Stress Disorder (PTSD). The score ranges from 0-80 with a higher score indicating worse symptoms. It is considered the gold standard for diagnosis and symptoms assessment in PTSD clinical studies.
Interventions
- DRUG Glecaprevir / Pibrentasvir Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-04-01 |
| Est. Completion | 2024-04-15 |
| Phase | Phase 2 |
What the finished NCT05446857 record still lists
NCT05446857 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Glecaprevir / Pibrentasvir Pill is the first listed.
NCT05446857 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05446857 about?
NCT05446857 is a clinical study titled "Glecaprevir/Pibrentasvir for the Treatment of PTSD". An open-label pilot study to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection (HCV).
What is the current status of trial NCT05446857?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2023-04-01. Estimated completion is 2024-04-15.
What interventions are being tested in trial NCT05446857?
The interventions under investigation include: Glecaprevir / Pibrentasvir Pill (DRUG).
Who is sponsoring clinical trial NCT05446857?
This trial is sponsored by White River Junction Veterans Affairs Medical Center, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05446857's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI